Garth Kinberger

SVP of Chemistry at Atalanta Therapeutics

Speaker

Dr Garth Kinberger is Vice President of Chemistry at Atalanta Therapeutics where he leads research chemistry and CMC. Dr. Kinberger joined Atalanta in 2021 and has contributed to the advancement of the divalent siRNA platform, leading to the progression of two programs into preclinical development.

Prior to Atalanta, Dr. Kinberger worked at Regulus Therapeutics, led chemistry and CMC, conducted research on microRNA therapeutics, and contributed to the discovery of Farabursen for the treatment of ADPKD.

After Dr. Kinberger received his PhD in Chemistry from UCSD, he began his career at Ionis Pharmaceuticals in the medicinal chemistry of oligonucleotide therapeutics. Dr. Kinberger is the author of 30 scientific publications and inventor of 15 submitted patents.